Romiplostim N01 in Chemoradiotherapy-induced Aplastic Anemia

Inclusion Criteria: 1. Age ≥ 18 years old; 2. Diagnosed with relapsed/refractory chemoradiotherapy-induced AA. Relapsed/ refractory was defined as patients who had no response to at least 3 months of cyclosporine or thrombopoietin receptor agonists (TPO-RAs) such as eltrombopag; 3. At least one of the following conditions must be met: hemoglobin \< 90 g/ L, platelet count \< 30×109/L, neutrophil count \< 1.0×109/L; 4. With baseline liver and kidney functions \<2 upper limit of normal (ULN); 5. Without active infection that cannot be controlled by standard treatment; 6. Signed the informed consent; 7. ECOG score ≤ 2; Exclusion Criteria: 1. Had other primary or secondary bone marrow failure (BMF) diseases, such as Fanconi anemia, congenital keratinization disorder, etc.; 2. With evidence of clonal hematological bone marrow diseases (MDS, AML) in cytogenetics; 3. Paroxysmal nocturnal hemoglobinuria (PNH) clone ≥ 50%; 4. Received hematopoietic stem cell transplantation before enrollment; 5. Received ATG treatment before enrollment; 6. Severe bleeding or infection that cannot be controlled by standard treatment; 7. Allergic or intolerant to romiplostim N01; 8. Active infections of HIV, HCV, or HBV, liver cirrhosis, or portal hypertension 9. History of malignant tumors within 5 years; 10. History of arterial or venous thrombosis; 11. Pregnant or lactating patients; 12. Participated in other clinical trials within 3 months.